PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
0.49%
Gross profit growth under 50% of TRVN's 27.07%. Michael Burry would be concerned about a severe competitive disadvantage.
56.85%
EBIT growth above 1.5x TRVN's 14.24%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
54.90%
Operating income growth above 1.5x TRVN's 14.24%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
56.85%
Positive net income growth while TRVN is negative. John Neff might see a big relative performance advantage.
56.86%
Positive EPS growth while TRVN is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
56.86%
Positive diluted EPS growth while TRVN is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-0.00%
Share reduction while TRVN is at 0.01%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while TRVN is at 0.01%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
28.81%
OCF growth at 75-90% of TRVN's 37.31%. Bill Ackman would demand better working capital management or cost discipline.
28.81%
FCF growth 75-90% of TRVN's 37.31%. Bill Ackman might push for improved capital allocation or operational changes to match the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while TRVN stands at 1106.46%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
95.99%
10Y OCF/share CAGR above 1.5x TRVN's 49.15%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
56.40%
Positive OCF/share growth while TRVN is negative. John Neff might see a comparative advantage in operational cash viability.
-114.69%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
96.39%
Net income/share CAGR above 1.5x TRVN's 60.68% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
45.76%
Positive 5Y CAGR while TRVN is negative. John Neff might view this as a strong mid-term relative advantage.
32.63%
Positive short-term CAGR while TRVN is negative. John Neff would see a clear advantage in near-term profit trajectory.
-96.80%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-86.34%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-81.50%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.20%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-26.00%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-9.98%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-36.64%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-70.64%
We cut SG&A while TRVN invests at 10.57%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.